While injectable BPC-157 enters systemic circulation immediately, oral administration allows both local GI therapeutic effects and systemic distribution
It is not a medicinal product, food, cosmetic, or dietary supplement, and is not approved for human or veterinary use
Clinical Trial of a Leucotriene B4 Receptor Antagonist, BIIL 284, in Patients With Rheumatoid Arthritis
Older individuals: Aging leads to decreased gastric acid production, reducing B-12 release from bound proteins
Safety, Side Effects & Regulatory Notes Early research suggests BPC-157 is well-tolerated in animals and limited human studies, but long-term effects remain unknown
For 48 hours following your treatment, refrain from heavy activity